JNJ 38877618

Drug Profile

JNJ 38877618

Alternative Names: JNJ-38877618; OMO 1

Latest Information Update: 21 Mar 2016

Price : $50

At a glance

  • Originator Janssen Pharmaceutica
  • Developer Janssen-Cilag; Octimet Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 08 May 2017 Octimet Oncology plans a phase I/II trial for Solid tumours (Metastatic disease, Inoperable/Unresectable) in United Kingdom (NCT03138083)
  • 15 Oct 2013 Janssen-Cilag plans a phase I trial for Healthy volunteers in the UK (NCT01964872)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top